MARC record from Internet Archive

LEADER: 06513cam 2200973Ia 4500
001 ocn272309273
003 OCoLC
005 20180816212018.0
008 081117s2008 njua ob 001 0 eng d
006 m o d
007 cr cn|||||||||
010 $a 2007940763
040 $aGW5XE$beng$epn$cGW5XE$dEBLCP$dIDEBK$dOCLCQ$dOH1$dYDXCP$dAU@$dCSU$dCDX$dCEF$dOCLCF$dBEDGE$dOCLCQ$dSLY$dDEBSZ$dE7B$dOCLCQ$dTXI$dOCLCQ$dUAB$dESU$dOCLCQ$dYDX$dVT2$dOCLCO$dOCLCA
019 $a242355019$a254166558$a271737035$a402230016$a756438029$a880108670$a908039377$a1005747064$a1044298762$a1048245832
020 $a9781597452748
020 $a1597452742
020 $a9781588299307$q(hbk.)
020 $a1588299309$q(hbk.)
035 $a(OCoLC)272309273$z(OCoLC)242355019$z(OCoLC)254166558$z(OCoLC)271737035$z(OCoLC)402230016$z(OCoLC)756438029$z(OCoLC)880108670$z(OCoLC)908039377$z(OCoLC)1005747064$z(OCoLC)1044298762$z(OCoLC)1048245832
037 $a978-1-58829-930-7$bSpringer$nhttp://www.springerlink.com
050 4 $aRS431.A64$bC54 2008eb
060 4 $aQZ 267 C514 2008
082 04 $a571.8/4377$222
084 $aR979. 1$2clc
245 00 $aCheckpoint responses in cancer therapy /$cedited by Wei Dai.
260 $aTotowa, NJ :$bHumana Press,$c2008.
300 $a1 online resource (xiii, 314 pages) :$billustrations.
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aCancer drug discovery and development
504 $aIncludes bibliographical references and index.
588 0 $aPrint version record.
505 0 $aRB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?
520 $aExtensive research has uncovered a set of molecular surveillance mechanisms - commonly called "checkpoints"--Which tightly monitor cell-cycle processes. Today's anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book's distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
650 0 $aAntineoplastic agents.
650 0 $aCell cycle$xRegulation.
650 07 $aCell cycle$xRegulation.$2cct
650 07 $aNeoplasms$xdrug therapy.$2cct
650 07 $aOncogenes$xgenetics.$2cct
650 07 $aCell Transformation, Neoplastic$xdrug effects.$2cct
650 07 $aCell Proliferation$xdrug effects.$2cct
650 07 $aGene Expression Regulation, Neoplastic.$2cct
650 07 $aAntineoplastic Agents$xpharmacology.$2cct
650 07 $aAntineoplastic agents.$2cct
650 7 $aBiome decine.$2eclas
650 7 $aSciences de la vie.$2eclas
650 7 $aAntineoplastic agents.$2fast$0(OCoLC)fst00810595
650 7 $aCell cycle$xRegulation.$2fast$0(OCoLC)fst01200944
650 2 $aNeoplasms$xdrug therapy.
650 2 $aOncogenes$xgenetics.
650 2 $aCell Transformation, Neoplastic$xdrug effects.
650 2 $aCell Proliferation$xdrug effects.
650 2 $aGene Expression Regulation, Neoplastic.
650 2 $aAntineoplastic Agents$xpharmacology.
655 4 $aElectronic books.
700 1 $aDai, Wei,$cPh. D.
776 08 $iPrint version:$tCheckpoint responses in cancer therapy.$dTotowa, NJ : Humana Press, 2008$z9781588299307$z1588299309$w(DLC) 2007940763$w(OCoLC)244659248
830 0 $aCancer drug discovery and development.
856 40 $3Ebook Library$uhttp://public.eblib.com/choice/publicfullrecord.aspx?p=371526
856 40 $3ebrary$uhttp://site.ebrary.com/id/11029353
856 40 $3MyiLibrary$uhttp://www.myilibrary.com?id=139799
856 40 $3OhioLINK$uhttp://rave.ohiolink.edu/ebooks/ebc/9781597452748
856 40 $3SpringerLink$uhttp://dx.doi.org/10.1007/978-1-59745-274-8
856 41 $3MyiLibrary, Table of contents$uhttp://www.myilibrary.com?id=139799&ref=toc
856 41 $3Table of contents$uhttp://catdir.loc.gov/catdir/toc/fy0805/2007940763.html
856 40 $uhttps://link.springer.com/openurl?genre=book&isbn=978-1-58829-930-7
856 4 $zScholars Portal Books$uhttp://proxy.library.carleton.ca/login?url=http://books.scholarsportal.info/viewdoc.html?id=/ebooks/ebooks0/springer/2009-12-01/5/9781597452748
856 40 $zSpringerLink$uhttp://proxy.library.carleton.ca/login?url=http://dx.doi.org/10.1007/978-1-59745-274-8
856 40 $uhttps://link.springer.com/10.1007/978-1-59745-274-8
938 $aCoutts Information Services$bCOUT$n8654958
938 $aEBL - Ebook Library$bEBLB$nEBL371526
938 $aebrary$bEBRY$nebr11029353
938 $aProQuest MyiLibrary Digital eBook Collection$bIDEB$n139799
938 $aYBP Library Services$bYANK$n2855229
029 1 $aAU@$b000043373578
029 1 $aAU@$b000058156554
029 1 $aCDX$b8654958
029 1 $aDEBSZ$b430680368
029 1 $aHEBIS$b201680149
029 1 $aNZ1$b13072498
029 1 $aAU@$b000060388399
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 352 OTHER HOLDINGS